PD-L1 (Extracellular region) M051 Antibody
Applications
Reactivity
| Overview | |
| Catalog # | bsm-70603M-100uL |
| Product Name | PD-L1 (Extracellular region) M051 Antibody |
| Applications |
WB
IP
|
| Specificity | Clone M051 mouse monoclonal antibody detects a 45-55 kDa* protein on SDS-PAGE "Native" or denatured immunoblots of human recombinant PD-L1 extracellular region, and human lung tissue. The antibody works for western blot, immunoprecipitation, immunocytochemistry, and ELISA capture. |
| Reactivity | Human |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Mouse |
| Source | Clone (M051) was generated from a recombinant protein that included the extracellular region of human PD-L1 protein. |
| Clonality | Monoclonal |
| Clone # | M051 |
| Isotype | IgG1 |
| Concentration | Lot Dependent |
| Purification | Purified by Protein G. |
| Storage Buffer | PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage Condition | Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target | |
| Swiss Prot | Q9NZQ7 |
| Synonyms | Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1 |
| Background | Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The B7 family members have conserved regions that include extracellular IgV and IgC domains, and a short cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas. PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, which promotes tumor survival. The blockage of the PD1/PD-L1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. Several therapies that target PD1/PD-L1 pathways are currently in use or in clinical trials |
| Application Dilution | |
| WB | 1:300-5000 |
| IP | 1-2ug |
Frequently asked questions
Which applications is PD-L1 (Extracellular region) M051 Antibody (bsm-70603M) validated for, and at what dilution?
bsm-70603M is validated for WB (1:300-5000); IP (1-2ug). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does PD-L1 (Extracellular region) M051 Antibody (bsm-70603M) react with?
Tested reactivity: Human.
How should bsm-70603M be stored?
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. Storage buffer: PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol
What immunogen was used to raise PD-L1 (Extracellular region) M051 Antibody (bsm-70603M)?
Clone (M051) was generated from a recombinant protein that included the extracellular region of human PD-L1 protein.